Gastroenterology
Volume 135, Issue 1 , Pages 100-110 , July 2008

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

  • Vlad Ratziu

      Affiliations

    • Université Pierre et Marie Curie Paris VI, Assistance Publique-Hôpitaux de Paris, Service d'Hépatogastroentérologie, Paris, France
    • Corresponding Author InformationAddress requests for reprints to: Prof Vlad Ratziu, Hôpital Pitié-Salpetriére, 47-83 Bd de l'Hôpital, Paris, France. fax: (33) 1 42 16 10 49.
    • ,
  • Philippe Giral

      Affiliations

    • INSERM UMRS_893, CdR Saint-Antoine, Paris, France
    • ,
  • Sophie Jacqueminet

      Affiliations

    • Université Pierre et Marie Curie Paris VI, Assistance Publique-Hôpitaux de Paris, Service d'Endocrinologie, Paris, France
    • ,
  • Fréderic Charlotte

      Affiliations

    • Université Pierre et Marie Curie Paris VI, Assistance Publique-Hôpitaux de Paris, Service de Diabétologie, Paris, France
    • ,
  • Agnès Hartemann–Heurtier

      Affiliations

    • Université Pierre et Marie Curie Paris VI, Assistance Publique-Hôpitaux de Paris, Service d'Endocrinologie, Paris, France
    • ,
  • Lawrence Serfaty

      Affiliations

    • Laboratoire d'Anatomie Pathologique, Hôpital Pitié-Salpêtrière, Paris, France
    • ,
  • Philippe Podevin

      Affiliations

    • Assistance Publique-Hôpitaux de Paris, Service d'Hépatologie, Hôpital Saint-Antoine, Paris, France
    • ,
  • Jean–Marc Lacorte

      Affiliations

    • Fédération de Biochimie, Hôpital Pitié-Salpêtrière, Paris, France
    • ,
  • Carole Bernhardt

      Affiliations

    • Université Pierre et Marie Curie Paris VI, Assistance Publique-Hôpitaux de Paris, Service d'Hépatogastroentérologie, Paris, France
    • ,
  • Eric Bruckert

      Affiliations

    • INSERM UMRS_893, CdR Saint-Antoine, Paris, France
    • ,
  • André Grimaldi

      Affiliations

    • Université Pierre et Marie Curie Paris VI, Assistance Publique-Hôpitaux de Paris, Service d'Endocrinologie, Paris, France
    • ,
  • Thierry Poynard

      Affiliations

    • Université Pierre et Marie Curie Paris VI, Assistance Publique-Hôpitaux de Paris, Service d'Hépatogastroentérologie, Paris, France
    • ,
  • LIDO Study Group

Received 13 November 2007 ,Accepted 20 March 2008.

References 

  1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923
  2. Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed?. J Hepatol. 2005;42:12–14
  3. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112
  4. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873
  5. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121
  6. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–1493
  7. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–689
  8. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–140
  9. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–1192
  10. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol. 2005;43:1060–1066
  11. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–2090
  12. Skarfors ET, Wegener TA, Lithell H, et al. Physical training as treatment for type 2 (non-insulin-dependent) diabetes in elderly men (A feasibility study over 2 years). Diabetologia. 1987;30:930–933
  13. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008–1017
  14. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188–196
  15. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307
  16. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20:23–28
  17. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–1123
  18. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321
  19. Brunt EM, Janney CG, DiBisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474
  20. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10
  21. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46:424–429
  22. Friedman SL, Bansal MB. Reversal of hepatic fibrosis—fact or fantasy?. Hepatology. 2006;43:S82–S88
  23. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663–678
  24. Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89:4312–4319
  25. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655–1663
  26. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–2099
  27. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest. 2006;116:581–589
  28. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169–2176
  29. Kubota N, Terauchi Y, Kubota T, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006;281:8748–8755
  30. Dixon JB, Bhathal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647–1654
  31. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94:2557–2562
  32. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998–1003
  33. Ueki K, Kondo T, Tseng YH, et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A. 2004;101:10422–10427
  34. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11:191–198
  35. Fromenty B, Robin MA, Igoudjil A, et al. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004;30:121–138
  36. Li Z, Lin H, Yang S, et al. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology. 2002;123:1304–1310
  37. Feldstein AE, Canbay A, Guicciardi ME, et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol. 2003;39:978–983
  38. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA. 1999;282:1659–1664
  39. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med. 2005;37:347–356
  40. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345–32353
  41. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023–3028
  42. Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749–758
  43. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122:1924–1940
  44. McCullough AJ. Thiazolidinediones for nonalcoholic steatohepatitis—promising but not ready for prime time. N Engl J Med. 2006;355:2361–2363
  45. Marchesini G, Avagnina S, Barantani EG, et al. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest. 2005;28:333–339
  46. Lee DH, Silventoinen K, Jacobs DR, et al. Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab. 2004;89:5410–5414
  47. Nawrocki AR, Rajala MW, Tomas E, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2006;281:2654–2660
  48. US Food and Drug Administration. FDA briefing document: joint meeting of the Endocrinologic and Metabolic Drug Advisory Committee and the Drug Safety and Risk Management Committee. http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007-4308m1-final.pdfAccessed September 6, 2007
  49. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother. 2007;41:2014–2018
  50. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–778

 This was an investigator-initiated trial, and GlaxoSmithKline Pharmaceuticals had no direct or indirect involvement in the design of the trial, data collection, or preparation or submission of the manuscript. GlaxoSmithKline provided rosiglitazone and placebo for this trial and partly funded the trial. None of the authors have a personal conflict of interest with the manufacturer of any of the marketed thiazolidinediones. V.R. is a consultant to Astellas, Gilead, Pfizer, Sanofi-Aventis, and Trophos. T.P. is a consultant for and owns 15% of BioPredictive, a company that markets FibroTest and SteatoTest.

 The members of the Liver Injury in Diabetes and Obesity (LIDO) Study Group are as follows: André Grimaldi, Philippe Giral, Eric Bruckert, Arnaud Basdevant, Karine Clement, Agnès Hartemann-Heurtier, Sophie Gombert, Francine Lamaison, Dominique Simon, Joseph Moussalli, Pascal Lebray, Christiane Coussieu, Djamila Messous, Françoise Imbert-Bismut, Yves Benhamou, Cecilia D'Arrondel, Carole Bernhardt, Isabelle Ravalet, Hôpital Pitié-Salpêtrière; Philippe Podevin, Hôpital Cochin; Christian Boitard, Etienne Larger, Hôpital Hotel-Dieu; Lawrence Serfaty, Chantal Housset, Jacqueline Capeau, Hôpital Saint Antoine, all in Paris, France..

PII: S0016-5085(08)00630-6

doi: 10.1053/j.gastro.2008.03.078

Gastroenterology
Volume 135, Issue 1 , Pages 100-110 , July 2008

Article Tools

* Image Usage & Resolution